When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: What is the next step?

Annals of the Rheumatic Diseases

Volumn 67, Issue 11, 2008, Pages 1497-1498

  Smolen, Josef S ^a   Weinblatt, Michael E ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DRUG EFFECT; DRUG INDICATION; EDITORIAL; HUMAN; INFECTION; LIPID BLOOD LEVEL; LIVER TOXICITY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54349087856     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2008.098111     Document Type: Editorial

References (25)

1. Weinblatt ME. Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003;62(Suppl ii):ii94-6.
2. Smolen JS, Aletaha D, Koeller M, Weisman M, Emery P. New therapies for the treatment of rheumatoid arthritis. Lancet 2007;370:1861- 74.
3. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one antitumor necrosis factor a agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
4. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66(Suppl 3):iii2-22.
5. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Calabozo M, Urkaregi A, Quintana A. Tumor necrosis factor α drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Dis 2008;9:doi:10.1186/1471-2474-9-52.
6. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353:1114-23.
7. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2739-806.
8. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
9. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
10. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;34(Suppl 1):19-22.
11. Emery P, Keystone E, Tony H-P, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008;67:1516-23.
12. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
13. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
14. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
15. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
16. Emery P, Fleischmann RM, Filipowicz-Sosnowska A, Schechtman J, Ramos-Remus C, Gomez-Reino JJ, et al. Rituximab in rheumatoid arthritis: a double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2005;52:abstract 1917.
17. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
18. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-74.
19. Walther Z, May LT, Sehgal PB. Transcriptional regulation of the interferon-beta 2/B cell differentiation factor BSF-2/hepatocyte-stimulating factor gene in human fibroblasts by other cytokines. J Immunol 1988;140:974-7.
20. Smolen J, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab, a new human anti-TNF α monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-α agent(s): results of the randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2008;67(Suppl II):50.
21. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Bud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
22. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
23. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
24. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
25. Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594- 602.